Business Context and Reporting Period
Actinium Pharmaceuticals, Inc. (ATNM) filed this Form 8-K on May 15, 2020. The filing addresses a delay in the submission of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
Key Financial Metrics
This filing does not contain specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document serves solely as a notification regarding a reporting delay.
Material Changes
The primary material event is the postponement of the Form 10-Q filing deadline. The Company cited severe disruptions in transportation and limited access to its facility due to the COVID-19 pandemic. These circumstances resulted in limited support from staff and professional advisors, compounded by the small size of the accounting team.
Guidance, Outlook, and Risks
Outlook: The Company expects to file the delayed Form 10-Q no later than June 29, 2020, which is 45 days from the original deadline. This timeline complies with the SEC Order dated March 25, 2020, which modified exemptions for public companies during the pandemic.
Risks: The filing references a Risk Factor included in the Company's Annual Report on Form 10-K (filed May 8, 2020) regarding the continuing developments of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the actual filing date of the Form 10-Q for the quarter ended March 31, 2020, to ensure it was submitted by June 29, 2020.
- Review the Form 10-K filed on May 8, 2020, for detailed risk factors related to COVID-19.
- Monitor subsequent filings for any updates on the Company's operational capacity and financial status post-pandemic disruptions.